Gene therapy AB-1005 was first administered to a patient with multiple system atrophy (Parkinsonian type).

Published Date: 23 Nov 2023

The study is anticipated to comprise nine MSA-parkinsonian type patients, ages 35 to 75, who will be randomized 2:1 to receive either investigational AB-1005 or sham surgery. It will be double-blind and placebo-controlled.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot